The US Food and Drug Administration has granted breakthrough therapy designation to an EGFR tyrosine kinase inhibitor for the first-line treatment of EGFR-positive non-small cell lung cancer. READ MORE

News

The US Food and Drug Administration has granted breakthrough therapy designation to an EGFR tyrosine kinase inhibitor for the first-line treatment of EGFR-positive non-small cell lung cancer.

READ MORE

The US Food and Drug Administration has approved a therapy to treat adults with advanced, metastatic breast cancer that has progressed on endocrine therapy.

READ MORE

The US Food and Drug Administration has indicated nivolumab for intravenous use in patients with previously treated liver cancer.

READ MORE

The US Food and Drug Administration expanded the approval of a targeted therapy to treat gastric or gastroesophageal junction cancer.

READ MORE